Morgan Stanley analyst Vincent Andrews raised the firm's price target on Corteva to $95 from $84 and keeps an Overweight rating on the shares. The market is valuing "New Corteva" like a no-growth commodity chemical maker, which is "too bearish" as the investment debate shifts to New Corteva's standalone growth rate, the analyst tells investors.
